tbuckley/cabot-search huggingface dataset:
The diameter factor of aligned membranes facilitates wound healing by promoting epithelialization in an immune way
Authors: Chenbing Wang, Chenyu Chu, Xiwen Zhao, Yang Yang, Chen Hu, Li Liu, Jidong Li, Yili Qu, Yi Man
Journal: Bioactive Materials (2021)

Topographical properties, such as pattern and diameter, of biomaterials play important roles in influencing cell activities and manipulating the related immune response during wound healing. We prepared aligned electrospinning membranes with different fiber diameters, including 319 ± 100 nm (A300), 588 ± 132 nm (A600), and 1048 ± 130 nm (A1000), by adjusting the distance from the tip to the collector, the injection rate, and the concentration of the solution. The A300 membranes significantly improved cell proliferation and spreading and facilitated wound healing (epithelization and vascularization) with the regeneration of immature hair follicles compared to the other membranes. Transcriptomics revealed the underlying molecular mechanism that A300 could promote immune-related processes towards a pro-healing direction, significantly promoting keratinocyte migration and skin wound healing. All the results indicated that wound healing requires the active participation of the immune process, and that A300 was a potential candidate for guided skin regeneration applications.
1622P The impact of COVID-19 on cancer treatment delivery in Sub-Saharan Africa
Authors: K. Merrell, P. Ochieng, E.B. Osei - Bonsu, E. Seife, K. Kemper, K. Begna, S. Bussman, T. Leavitt, O. Acheamfour, V. Vanderpuye, A. Manirakiza, T. DeWees, E. Addison
Journal: Annals of Oncology (2021)
Monitoring of Programmed Cell Death Ligand-1 Blockade Using FDG PET/CT for Microsatellite Instability-High Metastatic Breast Cancer
Authors: Ayumi Kawamata, Shinsuke Sasada, Akiko Emi, Norio Masumoto, Takayuki Kadoya
Journal: Clinical Nuclear Medicine (2021)

Microsatellite instability-high/mismatch repair deficiency is one of biomarkers predicting the response to pembrolizumab, an immune checkpoint inhibitor for metastatic solid tumors. A 44-year-old woman with stage IIIC right breast cancer was treated with mastectomy and axillary node dissection after primary systemic chemotherapy followed by radiation, chemotherapy, and hormonal therapy. Eighteen months after surgery, recurrent diseases were revealed and refractory to multiple treatments. The recurrent site biopsy showed microsatellite instability-high, and programmed cell death ligand-1 inhibitor pembrolizumab was administrated. FDG PET/CT showed complete metabolic response over 12 months and is useful to monitor the response of active immunotherapy.
1673P Efficacy and safety of 5 mg olanzapine for the prevention of carboplatin-induced nausea and vomiting in patients with thoracic malignancies: A prospective multicenter phase II study
Authors: Y. Fujita, H. Iihara, M. Shimokawa, C. Sakai, S. Ikemura, C. Hirose, M. Kotake, N. Funaguchi, T. Gomyo, H. Imai, J. Hakamata, D. Kaito, K. Minato, T. Arai, H. Kawazoe, A. Suzuki, Y. Ohno, H. Okura
Journal: Annals of Oncology (2021)
949P Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)
Authors: L. Shi, C. Zhou, X. Long, H. Li, C. Chen, C. Peng, P. Li, J. Li, S. Gu, B. Liang, W. Liao
Journal: Annals of Oncology (2021)
822TiP BFR ESS: A randomized phase II trial from the GSF/GETO French group evaluating the impact of interruption versus maintenance of aromatase inhibitors in patients with advanced or metastatic low grade endometrial stromal sarcoma after at least 3 years of therapy
Authors: I.L. Ray-Coquard, E. Bompas, C. Cropet, M. Donnat, F. Bertucci, L. Chaigneau, S. Metzger, A. Dufresne, C. Guillemet, C. Pacaut Vassal, L. Vénat-Bouvet, H. Vegas, S. Piperno-Neumann, M. Fabbro, J-Y. Blay, P. Dubray-Longeras, A.M. Savoye, M. Brahmi, A. Floquet
Journal: Annals of Oncology (2021)
1412P Palliative stents in a large cohort of advanced gastroesophageal cancers (GOC): Factors associated with long term survival
Authors: C. Hannon, B.H.R.D. Paula, M. Goksu, G. Corbett, N. Carroll, C.A.M.D. Sousa, E. Smyth
Journal: Annals of Oncology (2021)
Most deprived areas in England have fastest growing waiting lists, says think tank
Authors: Elisabeth Mahase
Journal: BMJ (2021)

People in England’s most deprived areas are nearly twice (1.8 times) as likely to experience a wait of over a year for hospital treatment than those in the most affluent areas, the King’s Fund has warned.

The analysis, which looked at waiting lists in July 2021 for planned hospital treatment—such as knee and hip replacements, cataract surgery, and other common procedures—found that 7% of patients on waiting lists in the most deprived areas of the country have been waiting at least a year for treatment, compared with 4% in the least deprived areas.

Waiting lists for elective care in general are growing more quickly in deprived areas. …
Helen Salisbury: Official hesitancy is not helping
Authors: Helen Salisbury
Journal: BMJ (2021)

Doctor, should my teenager have the covid jab?" "Yes, I think that would be sensible.What do you think?" "Well, I just don't know, doctor-the vaccine experts said it was difficult to decide, so what makes you so certain?"I'm sure that variations on this conversation are taking place up and down the country.Meanwhile, infections in children are soaring and, just three weeks into the new school term in
Unravelling the unmet needs of patients with severe dyspnoea: a case for palliative oxygen
Authors: Abebaw Mengistu Yohannes
Journal: European Respiratory Journal (2021)

<b>There is a great unmet need for palliative oxygen in patients with refractory dyspnoea from advanced non-malignant diseases, which requires further work in the management of this disabling symptom</b>https://bit.ly/2RAcIdn
1032TiP A phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes
Authors: I-M. Svane, J.M. Santos, V. Cervera-Carrascon, R. Havunen, S. Sorsa, E. Ellebæk, T. Monberg, M. Donia, A. Khammari, B. Dréno, A. Hemminki
Journal: Annals of Oncology (2021)
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT
Authors: Kazuma Oyama, Robert P. Giugliano, Michael A. Blazing, Jeong-Gun Park, Andrew M. Tershakovec, Marc S. Sabatine, Christopher P. Cannon, Eugene Braunwald
Journal: Journal of the American College of Cardiology (2021)
81P Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as predictors of survival in patients (P) with solid tumors treated with immune-checkpoint inhibitors (ICI)
Authors: J. Garcia-Corbacho, A.E. González Navarro, I. Victoria, D. Moreno, L. Heredia, I. Ortiz de Landázuri, V. Díez-Guardia, E. Sanfeliu, A. Indacochea, L. Angelats, N. Viñolas, B. Mellado, T. Saurí, J. Maurel, L. Mezquita, E. Pineda, N. Basté, A. Prat, M. Juan, F. Schettini
Journal: Annals of Oncology (2021)
354P Extended dosing (12 cycles) vs. conventional dosing (6 cycles) of adjuvant temozolomide in adults with newly diagnosed high grade gliomas: A randomized, single-blind, two-arm, parallel-group controlled trial
Authors: S.A. Javadinia, K. Anvari, M. Seilaniantousi, M. Saghafi
Journal: Annals of Oncology (2021)
Two Wrongs Do Not Always Make a Right
Authors: Julio Perez-Downes, Fred Kusumoto, Nora Goldschlager
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
Authors: E. Yu, J.M. Piulats, G. Gravis, P.C.C. Fong, T. Todenhöfer, B. Laguerre, J.A. Arranz Arija, S. Oudard, C. Massard, M. Stoeckle, L.T. Nordquist, J. Carles, M.P. Kolinsky, M. Augustin, H. Gurney, A. Tafreshi, X.T. Li, C.H. Poehlein, C. Schloss, J.S. de Bono
Journal: Annals of Oncology (2021)
1117P Mutational landscape of large cell neuroendocrine lung carcinoma: Molecular characterization using next generation sequencing
Authors: M. San Roman-Gil, L. Sanz-Gómez, J. Chamorro-Pérez, Y. Lage, M.E.O. Garcia, A. Gomez, E. Corral de la Fuente, D.I. Rosero-Rodríguez, V. Albarrán Fernández, J. Pozas, P. Alvarez-Ballesteros, E.M. Vida-Navas, J.J. Soto-Castillo, J. Torres-Jiménez, J. Esteban-Villarrubia, I. Orejana-Martín, A. Benito Berlinches, P. Garrido Lopez
Journal: Annals of Oncology (2021)
Cholesterol 25-hydroxylase is a metabolic switch to constrain T cell–mediated inflammation in the skin
Authors: H. Takahashi, H. Nomura, H. Iriki, A. Kubo, K. Isami, Y. Mikami, M. Mukai, T. Sasaki, J. Yamagami, J. Kudoh, H. Ito, A. Kamata, Y. Kurebayashi, H. Yoshida, A. Yoshimura, H. W. Sun, M. Suematsu, J. J. O’Shea, Y. Kanno, M. Amagai
Journal: Science Immunology (2021)

Interleukin-27 (IL-27) is an immunoregulatory cytokine whose essential function is to limit immune responses. We found that the gene encoding cholesterol 25-hydroxylase (Ch25h) was induced in CD4
ワクチン接種は非曝露成人においてウイルス特異的T細胞レパートリーを再形成する【JST・京大機械翻訳】
Authors: Pan Yi-Gen, Aiamkitsumrit Benjamas, Bartolo Laurent, Wang Yifeng, Lavery Criswell, Marc Adam, V Holec Patrick, Rappazzo C. Garrett, Eilola Theresa, A Gimotty Phyllis, E Hensley Scott, Antia Rustom, I Zarnitsyna Veronika, E Birnbaum Michael, F Su Laura
Journal: Immunity (2021)
Accelerated decline in lung function in adults with a history of remitted childhood asthma
Authors: Shinichiro Miura, Hiroshi Iwamoto, Keitaro Omori, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Takeshi Masuda, Shintaro Miyamoto, Taku Nakashima, Kazunori Fujitaka, Hironobu Hamada, Akihito Yokoyama, Noboru Hattori
Journal: European Respiratory Journal (2021)

A significant number of children with asthma show remission in adulthood. Although these adults are often diagnosed with COPD in later life, the effect of clinically remitted childhood asthma on the decline in lung function during adulthood is uncertain. We examined whether clinical remission of childhood asthma was associated with an accelerated decline in lung function in apparently nonasthmatic adults.3584 participants (mean (range) age 48.1 (35-65) years) who did not have adulthood asthma and other lung diseases and had normal lung function at the baseline visit were included. They were categorised as those with remitted childhood asthma (n=121) and healthy controls (n=3463) according to their self-reported childhood asthma history. Spirometry was performed at baseline and follow-up visits.The mean follow-up was 5.3 years. Multivariate regression analysis showed that remitted childhood asthma and smoking were independently associated with a rapid decline in forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC). Smoking was an independent predictor of a rapid decline in FEV1/FVC. The annual decline in FEV1 and FVC was significantly greater in participants with remitted childhood asthma than in healthy controls, and the differences remained significant after adjusting for the propensity score.A history of clinically remitted childhood asthma is an independent risk factor for accelerated decline in lung function in adults. Remitted childhood asthma and smoking may additively accelerate the development of obstructive lung disease.
147P Genomic profile and response prediction of eribulin mesylate-based neoadjuvant chemotherapy in triple-negative breast cancer patients
Authors: T. Nishimura, N. Masuda, K. Kawaguchi, M. Takada, Y. Maeshima, S. Tanaka, R. Velaga, Y. Kikawa, T. Kadoya, H. Bando, R. Nakamura, Y. Yamamoto, T. Ueno, H. Yasojima, H. Ishiguro, S. Morita, S. Ohno, H. Haga, S. Ogawa, M. Toi
Journal: Annals of Oncology (2021)
1486P Clinicopathological characteristics and prognostic factors of ampullary cancer: A tertiary care centre experience over 10 years
Authors: A.K. Singla, D. Khosla, R. Kapoor, D. Kumar, R. Madan, K. Periasamy, S. Goyal, R. Gupta, V. Gupta
Journal: Annals of Oncology (2021)
1598P Acceptance of SARS-CoV-2 vaccination among patients with cancer undergoing immunosuppressive therapy: Portuguese study
Authors: M.J.P. de Sousa, C. Caramujo, N. Julio, J. Correia Magalhães, R. Basto, T. Fraga, I. Ferreira Gomes, I. Pazos, G. Sousa
Journal: Annals of Oncology (2021)
A global assessment of recent trends in gastrointestinal cancer and lifestyle‐associated risk factors
Authors: Lili Lu, Christina S. Mullins, Clemens Schafmayer, Sebastian Zeißig, Michael Linnebacher
Journal: Cancer Communications (2021)

Abstract Background Gastrointestinal (GI) cancers were responsible for 26.3% of cancer cases and 35.4% of deaths worldwide in 2018. This study aimed to analyze the global incidence, mortality, prevalence, and contributing risk factors of the 6 major GI cancer entities [esophageal cancer (EC), gastric cancer (GC), liver cancer (LC), pancreatic cancer (PC), colon cancer, and rectal cancer]. Methods Using the Global Cancer Observatory and the Global Health Observatory databases, we reviewed the current GI cancer incidence, prevalence, and mortality, analyzed the association of GI cancer prevalence with national human development indices (HDIs), identified the contributing risk factors, and estimated developing age‐ and sex‐specific trends in incidence and mortality. Results In 2020, the trend in age‐standardized rate of incidence of GI cancers closely mirrored that of mortality, with the highest rates of LC, EC, and GC in Asia and of colorectal cancer (CRC) and PC mainly in Europe. Incidence and mortality were positively, but the mortality‐to‐incidence ratio (MIR) was inversely correlated with the national HDI levels. High MIRs in developing countries likely reflected the lack of preventive strategies and effective treatments. GI cancer prevalence was highest in Europe and was also positively correlated with HDIs and lifestyle‐associated risk factors, such as alcohol consumption, smoking, obesity, insufficient physical activity, and high blood cholesterol level, but negatively correlated with hypertension and diabetes. Incidences of EC were consistently and those of GC mostly decreasing, whereas incidences of CRC were increasing in most countries/regions, especially in the younger populations. Incidences of LC and PC were also increasing in all age‐gender populations except for younger males. Mortalities were decreasing for EC, GC, and CRC in most countries/regions, and age‐specific trends were observed in PC and LC with a decrease in the younger but an increase in the older population. Conclusions On the global scale, higher GI cancer burden was accompanied, for the most part, by factors associated with the so‐called Western lifestyle reflected by high and very high national HDI levels. In countries/regions with very high HDI levels, patients survived longer, and increasing GI cancer cases were observed with increasing national HDI levels. Optimizing GI cancer prevention and improving therapies, especially for patients with comorbid metabolic diseases, are thus urgently recommended.
The Use of Intraoperative Transit Time Flow Measurement for Coronary Artery Bypass Surgery: Systematic Review of the Evidence and Expert Opinion Statements
Authors: Mario Gaudino, Sigrid Sandner, Gabriele Di Giammarco, Antonino Di Franco, Hirokuni Arai, Tohru Asai, Faisal Bakaeen, Torsten Doenst, Stephen E. Fremes, David Glineur, Teresa M. Kieser, Jennifer S. Lawton, Roberto Lorusso, Nirav Patel, John D. Puskas, James Tatoulis, David P. Taggart, Michael Vallely, Marc Ruel
Journal: Circulation (2021)

Transit time flow measurement (TTFM) allows quality control in coronary artery bypass grafting but remains largely underused, probably because of limited information and the lack of standardization. We performed a systematic review of the evidence on TTFM and other methods for quality control in coronary artery bypass grafting following PRISMA standards and elaborated expert recommendations by using a structured process. A panel of 19 experts took part in the consensus process using a 3-step modified Delphi method that consisted of 2 rounds of electronic voting and a final face-to-face virtual meeting. Eighty percent agreement was required for acceptance of the statements. A 2-level scale (strong, moderate) was used to grade the statements based on the perceived likelihood of a clinical benefit. The existing evidence supports an association between TTFM readings and graft patency and postoperative clinical outcomes, although there is high methodological heterogeneity among the published series. The evidence is more robust for arterial, rather than venous, grafts and for grafts to the left anterior descending artery. Although TTFM use increases the duration and the cost of surgery, there are no data to quantify this effect. Based on the systematic review, 10 expert statements for TTFM use in clinical practice were formulated. Six were approved at the first round of voting, 3 at the second round, and 1 at the virtual meeting. In conclusion, although TTFM use may increase the costs and duration of the procedure and requires a learning curve, its cost/benefit ratio seems largely favorable, in view of the potential clinical consequences of graft dysfunction. These consensus statements will help to standardize the use of TTFM in clinical practice and provide guidance in clinical decision-making.
891P Landscape of NOTCH1 genomic alterations (GA) in head and neck squamous cell carcinoma (HNSCC) and T-ALL
Authors: K. Ikenberg, G. Bratslavsky, J. Jacob, N.A. Danziger, A. Necchi, P.E. Spiess, P. Grivas, C. Pauli, H. Moch, J.S. Ross
Journal: Annals of Oncology (2021)
653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564
Authors: T.K. Choueiri, P. Tomczak, S.H. Park, B. Venugopal, S. Symeonides, J. Hajek, T. Ferguson, Y-H. Chang, J.L. Lee, N. Haas, P. Sawrycki, N. Sarwar, M. Gross-Goupil, A. Thiery-Vuillemin, M. Mahave, T.L. Saretsky, P. Zhang, J. Willemann-Rogerio, D.I. Quinn, T.B. Powles
Journal: Annals of Oncology (2021)
1668TiP Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)
Authors: A. Dowlati, L.A. Byers, M.L. Johnson, R. Aljumaily, H. Prenen, A. Zhang, M. Minocha, A. Shetty, N. Hashemi Sadraei
Journal: Annals of Oncology (2021)
Potential residual confounders in an analysis of lifestyle factors and risk of incident systemic lupus erythematosus: comment on the article by Choi et al
Authors: Pei‐En Kao, Amy Ker, Cheng‐Ruei Yang, James Cheng‐Chung Wei
Journal: Arthritis & Rheumatology (2021)

Disclosureform Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Role of inorganic phosphate concentrations in in vitro activity of fosfomycin
Authors: Miriam Ortiz-Padilla, Inés Portillo-Calderón, Natalia Maldonado, José Rodríguez-Martínez, Belén de Gregorio-Iaria, Vicente Merino-Bohórquez, Jesús Rodríguez-Baño, Álvaro Pascual, Fernando Docobo-Pérez
Journal: Clinical Microbiology and Infection (2021)
eggNOG-mapper v2: Functional Annotation, Orthology Assignments, and Domain Prediction at the Metagenomic Scale
Authors: Carlos P Cantalapiedra, Ana Hernández-Plaza, Ivica Letunic, Peer Bork, Jaime Huerta-Cepas
Journal: Molecular Biology and Evolution (2021)

Even though automated functional annotation of genes represents a fundamental step in most genomic and metagenomic workflows, it remains challenging at large scales. Here, we describe a major upgrade to eggNOG-mapper, a tool for functional annotation based on precomputed orthology assignments, now optimized for vast (meta)genomic data sets. Improvements in version 2 include a full update of both the genomes and functional databases to those from eggNOG v5, as well as several efficiency enhancements and new features. Most notably, eggNOG-mapper v2 now allows for: 1) de novo gene prediction from raw contigs, 2) built-in pairwise orthology prediction, 3) fast protein domain discovery, and 4) automated GFF decoration. eggNOG-mapper v2 is available as a standalone tool or as an online service at http://eggnog-mapper.embl.de.
434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)
Authors: M. Fakih, G.S. Falchook, D.S. Hong, R.D. Yaeger, E. Chan, O. Mather, P. Cardona, T. Dai, J. Strickler
Journal: Annals of Oncology (2021)
What’s Wrong With Advance Care Planning?
Authors: R. Sean Morrison, Diane E. Meier, Robert M. Arnold
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
664P Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors
Authors: A.R. Kydd, M-J. Lee, S. Lee, S. Rastogi, N. Sato, L. Cordes, L. Ley, O. Sierra Ortiz, J.J. Wright, H. Streicher, S. Steinberg, B. Saraiya, S.K. Pal, P.N. Lara, A. Mortazavi, R. Costello, S. Niglio, D. Bottaro, J. Trepel, A.B. Apolo
Journal: Annals of Oncology (2021)